Immune Tolerance Induction in the Era of Emicizumab—Still the First Choice for Patients With Hemophilia A and Inhibitors?
52. Hamburger Hämophilie SymposionHämostaseologie(2022)
摘要
Introduction: The development of inhibitory antibodies is a severe complication of clotting factor replacement therapy in patients with severe hemophilia A (HA). Current World Federation of Hemophilia guidelines for hemophilia care indicate that eradication of inhibitors is best achieved through immune tolerance induction (ITI) therapy.
更多查看译文
关键词
immune tolerance induction,hemophilia,emicizumab—still,inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要